Title : Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.

Pub. Date : 2020

PMID : 32042320






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Conclusion: Our results for PDX models of LAR TNBC resistant to enzalutamide indicate that PIK3CA and AKT1 are potential therapeutic targets. enzalutamide AKT serine/threonine kinase 1 Homo sapiens